Jordi Rimola1, Núria Planell2, Sonia Rodríguez1, Salvadora Delgado3, Ingrid Ordás4, Anna Ramírez-Morros4, Carmen Ayuso5, Montse Aceituno6, Elena Ricart4, Aranzazu Jauregui-Amezaga4, Julián Panés4, Míriam Cuatrecasas7. 1. Department of Radiology, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. 2. 1] Bioinformatics Platform, CIBERehd, Barcelona, Spain [2] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain. 3. 1] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain [2] Department of Gastrointestinal Surgery, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. 4. 1] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain [2] Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. 5. 1] Department of Radiology, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain [2] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain. 6. Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. 7. 1] Department of Pathology-CDB, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain [2] Tumour Bank, Biobank Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Abstract
OBJECTIVES: Measurement of the component of fibrosis in Crohn's disease (CD) may have important therapeutic implications. The aim of this study was to characterize the Magnetic Resonance Imaging (MRI) findings that are differentially associated with the presence of fibrosis and those associated with inflammatory activity, using the pathological analysis of surgically resected intestinal lesions as reference standard. METHODS: MRI studies with identical imaging protocol of 41 CD patients who underwent elective bowel resection within 4 months before surgery were reviewed. MRI evaluated wall thickening, edema, ulcers, signal intensity at submucosa at 70 s and 7 min after gadolinium injection, stenosis, and pattern of enhancement in each phase of the dynamic study and changes on this pattern over time. Pathological inflammatory and fibrosis scores were classified into three grades of severity. RESULTS: In all, 44 segments from 41 patients were analyzed. The pathological intensity of inflammation was associated with the following MRI parameters: hypersignal on T2 (P=0.02), mucosal enhancement (P=0.03), ulcerations (P=0.01), and blurred margins (P=0.05). The degree of fibrosis correlated with the percentage of enhancement gain (P<0.01), the pattern of enhancement at 7 min (P<0.01), and the presence of stenosis (P=0.05). Using percentage of enhancement gain, MRI is able to discriminate between mild-moderate and severe fibrosis deposition with a sensitivity of 0.94 and a specificity of 0.89. CONCLUSIONS: MRI is accurate for detecting the presence of severe fibrosis in CD lesions on the basis of the enhancement pattern.
OBJECTIVES: Measurement of the component of fibrosis in Crohn's disease (CD) may have important therapeutic implications. The aim of this study was to characterize the Magnetic Resonance Imaging (MRI) findings that are differentially associated with the presence of fibrosis and those associated with inflammatory activity, using the pathological analysis of surgically resected intestinal lesions as reference standard. METHODS: MRI studies with identical imaging protocol of 41 CDpatients who underwent elective bowel resection within 4 months before surgery were reviewed. MRI evaluated wall thickening, edema, ulcers, signal intensity at submucosa at 70 s and 7 min after gadolinium injection, stenosis, and pattern of enhancement in each phase of the dynamic study and changes on this pattern over time. Pathological inflammatory and fibrosis scores were classified into three grades of severity. RESULTS: In all, 44 segments from 41 patients were analyzed. The pathological intensity of inflammation was associated with the following MRI parameters: hypersignal on T2 (P=0.02), mucosal enhancement (P=0.03), ulcerations (P=0.01), and blurred margins (P=0.05). The degree of fibrosis correlated with the percentage of enhancement gain (P<0.01), the pattern of enhancement at 7 min (P<0.01), and the presence of stenosis (P=0.05). Using percentage of enhancement gain, MRI is able to discriminate between mild-moderate and severe fibrosis deposition with a sensitivity of 0.94 and a specificity of 0.89. CONCLUSIONS: MRI is accurate for detecting the presence of severe fibrosis in CD lesions on the basis of the enhancement pattern.
Authors: J Panes; Y Bouhnik; W Reinisch; J Stoker; S A Taylor; D C Baumgart; S Danese; S Halligan; B Marincek; C Matos; L Peyrin-Biroulet; J Rimola; G Rogler; G van Assche; S Ardizzone; A Ba-Ssalamah; M A Bali; D Bellini; L Biancone; F Castiglione; R Ehehalt; R Grassi; T Kucharzik; F Maccioni; G Maconi; F Magro; J Martín-Comín; G Morana; D Pendsé; S Sebastian; A Signore; D Tolan; J A Tielbeek; D Weishaupt; B Wiarda; A Laghi Journal: J Crohns Colitis Date: 2013-04-11 Impact factor: 9.071
Authors: Michael J Steward; Shonit Punwani; Ian Proctor; Yvette Adjei-Gyamfi; Fiona Chatterjee; Stuart Bloom; Marco Novelli; Steve Halligan; Manuel Rodriguez-Justo; Stuart A Taylor Journal: Eur J Radiol Date: 2011-09-15 Impact factor: 3.528
Authors: Jeremy Adler; Scott D Swanson; Phyllissa Schmiedlin-Ren; Peter D R Higgins; Christopher P Golembeski; Alexandros D Polydorides; Barbara J McKenna; Hero K Hussain; Trevor M Verrot; Ellen M Zimmermann Journal: Radiology Date: 2011-01-28 Impact factor: 11.105
Authors: Jordi Rimola; Alejandro Forner; Maria Reig; Ramon Vilana; Carlos Rodríguez de Lope; Carmen Ayuso; Jordi Bruix Journal: Hepatology Date: 2009-09 Impact factor: 17.425
Authors: Shonit Punwani; Manuel Rodriguez-Justo; Alan Bainbridge; Rebecca Greenhalgh; Enrico De Vita; Stuart Bloom; Richard Cohen; Alastair Windsor; Austin Obichere; Anika Hansmann; Marco Novelli; Steve Halligan; Stuart A Taylor Journal: Radiology Date: 2009-07-27 Impact factor: 11.105
Authors: M Barat; C Hoeffel; M Bouquot; A S Jannot; R Dautry; M Boudiaf; K Pautrat; R Kaci; M Camus; C Eveno; M Pocard; P Soyer; A Dohan Journal: Eur Radiol Date: 2018-10-09 Impact factor: 5.315
Authors: F Rieder; D Bettenworth; C Ma; C E Parker; L A Williamson; S A Nelson; G van Assche; A Di Sabatino; Y Bouhnik; R W Stidham; A Dignass; G Rogler; S A Taylor; J Stoker; J Rimola; M E Baker; J G Fletcher; J Panes; W J Sandborn; B G Feagan; V Jairath Journal: Aliment Pharmacol Ther Date: 2018-06-19 Impact factor: 8.171
Authors: Gianluca Pellino; Emanuele Nicolai; Onofrio A Catalano; Severo Campione; Francesco P D'Armiento; Marco Salvatore; Alberto Cuocolo; Francesco Selvaggi Journal: J Crohns Colitis Date: 2015-11-15 Impact factor: 9.071